The largest registered human methylene blue trial in ageing: a phase 2 double-blind placebo-controlled study in 117 people with healthy ageing, mild cognitive impairment or mild Alzheimer's disease, measuring blood flow, connectivity, memory and attention – no longevity, lifespan or mortality endpoint.
A double-blind, placebo-controlled study that aims to investigate the effect of 2-week and 12-week administration of USP methylene blue (MB) on cerebral blood flow, functional connectivity, memory and attention cognitive abilities
registry record, Brief Summary field
The largest registered human methylene blue trial in ageing: a phase 2 double-blind placebo-controlled study in 117 people with healthy ageing, mild cognitive impairment or mild Alzheimer's disease, measuring blood flow, connectivity, memory and attention – no longevity, lifespan or mortality endpoint. Record field transcription from the registry entry (labelled a record field, confidence MEDIUM). Study type: interventional, randomised, double-blind, placebo-controlled, phase 2. N=117 actual. Country: USA. Dose: 2-week and 12-week USP methylene blue courses (dose per protocol, not in the summary field). Comparator: placebo plus active-control dyes FD&C Blue #2 and phenazopyridine (to preserve blinding of urine colour). Status: COMPLETED, primary completion 2022-04-21, results posted on the registry. No direct PDF exists for a registry record; source_url is the canonical study page. The point for C6 is that even the largest human ageing trial measured cognition and imaging, never longevity. Also filed as MTK-43 (claims C1, C6).
